title: Use of Vitamins K antagonists in non-valvular atrial fibrillation thromboembolic risk prevention in Burkina Faso.
abstract: BACKGROUND
  Atrial fibrillation is the commonest cardiac rythm disorder. Thromboembolic accidents are common complications that should be prevented by anticoagulant treatment. The aim of our study is to assess the use of vitamins K antagonists in the prevention of thromboembolic risk in atrial fibrillation.
  
  
  METHODS
  It was a descriptive retrospective study of patients folders, performed in the cardiology department from January 1st 2010 to December 31st 2011. The study included all patients with non valvular atrial fibrillation. Thromboembolic risk was assessed through the CHA2DS2VASc score, and hemorrhagic risk through the HAS-BLED score.
  
  
  RESULTS
  Atrial fibrillation accounted for 10.6% of all hospitalizations (103/970). Five patients had contra indication to anticoagulants. Non valvular AF was noticed in 68 cases (66%). The non valvular AF was chronic in 40 cases (59%) and paroxystic in eight cases (12%). The median age of the population was 64.5+13.8 years old. Median CHA2DS2VASc score was 3.9 + 1.6. Two patients had a score < 1. Sex, place of residence, age > 65, and cardiac failure did not interfere with prescription of vitamins K antagonists. Ischemic stroke and intra cavity thrombus were the indications for vitamins K antagonists' prescriptions. The median HAS-BLED score was 3.5 + 1.5. The rate of vitamins K antagonists use was 35.3%. One case of death due to hemorrhagic stroke was noticed.
  
  
  CONCLUSIONS
  Guidelines on thromboembolic risk prevention are poorly used in the cardiology department. But the use of scoring systems allows the assessment of vitamins K antagonists treatment benefit/risk in atrial fibrillation, and minimizes the hemorrhagic risk.
authors.affiliation: Department of Cardiology, University Hospital Yalgado Ouedraogo, Burkina Faso.
authors.forename: Aristide Relwendé
authors.initials: AR
authors.lastname: Yameogo
authors.affiliation: Department of Cardiology, University Hospital Yalgado Ouedraogo, Burkina Faso; Training Unit and Research in Health Sciences (UFR / SDS), University of Ouagadougou, Burkina Faso.
authors.forename: Jonas Koudougou
authors.initials: JK
authors.lastname: Kologo
authors.affiliation: Department of Cardiology, University Hospital Yalgado Ouedraogo, Burkina Faso.
authors.forename: Germain
authors.initials: G
authors.lastname: Mandi
authors.affiliation: Department of Cardiology, University Hospital Yalgado Ouedraogo, Burkina Faso.
authors.forename: Hervé Poko
authors.initials: HP
authors.lastname: Kabore
authors.affiliation: Department of Cardiology, University Hospital Yalgado Ouedraogo, Burkina Faso; Training Unit and Research in Health Sciences (UFR / SDS), University of Ouagadougou, Burkina Faso.
authors.forename: Georges Rosario Christian
authors.initials: GR
authors.lastname: Millogo
authors.affiliation: Department of Cardiology, University Hospital Yalgado Ouedraogo, Burkina Faso.
authors.forename: Arthur André Taryetba
authors.initials: AA
authors.lastname: Seghda
authors.affiliation: Department of Cardiology, University Hospital Yalgado Ouedraogo, Burkina Faso; Training Unit and Research in Health Sciences (UFR / SDS), University of Ouagadougou, Burkina Faso.
authors.forename: André Koudnoaga
authors.initials: AK
authors.lastname: Samadoulougou
authors.affiliation: Department of Cardiology, University Hospital Yalgado Ouedraogo, Burkina Faso; Training Unit and Research in Health Sciences (UFR / SDS), University of Ouagadougou, Burkina Faso.
authors.forename: Patrice
authors.initials: P
authors.lastname: Zabsonre
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D002050:Burkina Faso; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D000925:Anticoagulants; D014812:Vitamin K
keywords: Atrial fibrillation; Burkina Faso; stroke; vitamins K antagonists